Nominations are now being accepted for the 2020 Virtual Clinical Research Learning Institute!
Trial News & Events
As the first ever platform trial for amyotrophic lateral sclerosis (ALS), the HEALEY ALS Platform Trial is testing three proposed drug regimens and will add two more over the next several months.
NEALS is pleased to announce a half-day training session for investigators interested in participating in ALS research as a Site Investigator in a multi-center clinical trial.
The NEALS ALS GAP (ALS Genetic Access Program) provides clinical genetics services to pALS who are under the care of a registered NEALS clinician.
As the COVID-19 situation continues to evolve, we know it is of particular concern for the ALS community, both for clinical care and research trials.
NEALS is pleased to announce a full day training session for investigators interested in developing and conducting multi-center ALS clinical trials as Principal Investigators.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS.
Patient engagement in research is increasingly recognized as important across many countries and fields. In 2008, we conducted surveys that suggested a need for improved patient engagement in ALS research. We decided to create an ALS Clinical Research Learning Institute (ALS-CRLI) to facilitate direct interactions between researchers and people with ALS and their caregivers, toward ultimately improving engagement.
People with amyotrophic lateral sclerosis with a common mutation in the interleukin 6 receptor (IL6R) gene appear likely to have more severe disease symptoms and faster progression than ALS patients without this inherited gene variant, a study reports.
The Sean M. Healey & AMG Center at Mass General will launch the first platform trial for amyotrophic lateral sclerosis (ALS) to accelerate the development of effective and breakthrough treatments for people with ALS.